Revenue
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics, Inc. (VVOS)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M |
| Research & development | $100,000 | $100,000 | $100,000 | $200,000 | $200,000 | — | — |
| Operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M | $22.5M | $19.2M |
| Operating income | −$19.9M | −$11.2M | −$17.3M | −$25.0M | −$20.4M | −$12.0M | −$10.6M |
| EBITDAderived | −$18.6M | −$10.6M | −$16.7M | −$24.4M | −$19.6M | −$11.3M | −$9.8M |
| Net income | −$21.2M | −$11.1M | −$13.6M | −$23.8M | −$20.3M | −$12.1M | −$10.8M |
| Basic EPSper diluted share | -$2.07 | -$2.22 | -$11.14 | -$25.90 | -$0.96 | -$1.40 | -$0.95 |
| Diluted EPSper diluted share | -$2.07 | -$2.22 | -$11.14 | -$25.90 | -$0.96 | -$1.40 | -$0.95 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyCommon Stock · indirect | 308.8K | $1.34 | $413.9K | 1.35M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyCommon Stock · indirect | 1.04M | $1.34 | $1.40M | 1.04M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuySeries B Common Stock Warrant · derivative · indirect | 1.78M | $1.34 | $2.39M | 1.78M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuySeries A Common Stock Warrant · derivative · indirect | 1.78M | $1.34 | $2.39M | 1.78M |
| Mar 31, 2026Form 4 | V-Co Investors 3 LLC +1TenPercentOwner | BuyPre-Funded Warrant · derivative · indirect | 430.0K | $1.34 | $576.1K | 430.0K |